Clinical use of exhaled biomarkers in COPD

International Journal of COPD

Volumn 2, Issue 4, 2007, Pages 403-408

  O'Reilly, Philip ^a   Bailey, William ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

COPD; EBC; ENO; Exhaled breath condensate; Nitric oxide

Indexed keywords

8 ISOPROSTANE; ALDEHYDE; BIOLOGICAL MARKER; COLLAGEN; CORTICOSTEROID; ELASTIN; HYDROGEN PEROXIDE; INTERLEUKIN 6; ISOPROSTANE DERIVATIVE; MATRIX METALLOPROTEINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OXYGEN; PROLYLGLYCYLPROLINE; TRIPEPTIDE DERIVATIVE; UNCLASSIFIED DRUG;

ASTHMA; BREATH ANALYSIS; BRONCHODILATATION; CHEMOLUMINESCENCE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COLLAGEN DEGRADATION; COR PULMONALE; CORRELATION FUNCTION; DIAGNOSTIC KIT; DISEASE ACTIVITY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG TARGETING; ENZYME INHIBITION; EPITHELIUM CELL; EXPIRED AIR; FORCED EXPIRATORY VOLUME; FREEZE DRYING; HUMAN; LIPID PEROXIDATION; LIQUID CHROMATOGRAPHY; LONG TERM CARE; LUNG DISEASE; LUNG EMPHYSEMA; LUNG LAVAGE; MASS SPECTROMETRY; NON INVASIVE MEASUREMENT; NONHUMAN; OXIDATIVE STRESS; OXYGEN THERAPY; PNEUMONIA; PROTEIN ANALYSIS; PULMONARY HYPERTENSION; REVIEW; SMOKING; TREATMENT RESPONSE; VASODILATATION;

BIOLOGICAL MARKERS; COLLAGEN; EXHALATION; HUMANS; NITRIC OXIDE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; UNITED STATES;

EID: 38049105959     PISSN: 11769106     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Agusti AG et al. 1999, Serial measurements of exhaled nitric oxide during exacerbations of chronic obstructive pulmonary disease. Eur Respir J, 14:523-8.
2. [ATS] American Thoracic Society. 1999. Recommendations for standardized procedures for the on-line and off-line measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide in adults and children - 1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med, 160:2104-17.
3. Barnes PJ et al. 2006. Pulmonary biomarkers in chronic obstructive pulmonary disease. Am J Respir Cril Care Med, 174:6-14.
4. Biernacki WA, Kharitonov SA, Barnes PJ. 2003. Increased leukotriene B4 and 8-isoprostane in exhaled breath condensate of patients with exacerbations of COPD. Thorax, 58:294-8.
5. Bucchioni E et al. 2003. High levels of interleukin-6 in the exhaled breath condensate of patients with COPD. Respir Med, 97:1299-302.
6. Calverley PM et al. 2003. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax, 58:659-64.
7. Chanez P et al. 1997. Corticosteroid reversibility in COPD is related to features of asthma. Am J Respir Crit Care Med, 155:1529-34.
8. Clini E et al. 1998. Endogenous nitric oxide in patients with stable COPD: correlates with severity of disease. Thorax, 53:881-3.
9. Clini E et al. 2000. Production of endogenous nitric oxide in chronic obstructive pulmonary disease and patients with cor pulmonale. Correlates with echo-Doppler assessment. Am J Respir Crit Care Med, 162:446-50.
10. Corradi M et al. 1999. Increased exhaled nitric oxide in patients with stable chronic obstructive pulmonary disease. Thorax, 54:572-5.
11. Corradi M et al. 2003. Aldehydes in exhaled breath condensate of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 167:1380-6.
12. Croxton TL, Bailey WC. 2006. Long-term oxygen treatment in chronic obstructive pulmonary disease: recommendations for future research: an NHLBI workshop report. Am J Respir Crit Care Med, 174:373-8.
13. Croxton TL et al. 2002. Future research directions in chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 165:838-44.
14. De Benedetto BF et al. 2000. Validation of a new technique to assess exhaled hydrogen peroxide: results from normals and COPD patients. Monaldi Arch Chest Dis, 55:185-8.
15. De Benedetto BF et al. 2005. Long-term oral n-acetylcysteine reduces exhaled hydrogen peroxide in stable COPD. Pulm Pharmacol Ther, 18;A1-7.
16. Dekhuijzen PN et al. 1996. Increased exhalation of hydrogen peroxide in patients with stable and unstable chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 154:813-16.
17. Effros RM et al. 2003. A simple method for estimating respiratory solute dilution in exhaled breath condensates. Am J Respir Crit Care Med, 168:1500-5.
18. Effros RM et al. 2002. Dilution of respiratory solutes in exhaled condensates. Am J Respir Crit Care Med, 165:663-9.
19. Fabbri LM et al. 2003. Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 167:418-24.
20. Ferreira IM et al. 2001. Exhaled nitric oxide and hydrogen peroxide in patients with chronic obstructive pulmonary disease: effects of inhaled beclomethasone. Am J Respir Crit Care Med, 164:1012-15.
21. Gaston B et al. 1994. The biology of nitrogen oxides in the airways. Am J Respir Crit Care Med, 149:538-51.
22. Haddad IY et al. 1994. Quantitation of nitrotyrosine levels in lung sections of patients and animals with acute lung injury. J Clin Invest, 94:2407-13.
23. Hautamaki RD et al. 1997. Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. Science, 277:2002-4.
24. Hickman-Davis JM et al. 2002. Killing of Klebsiella pneumoniae by human alveolar macrophages. Am J Physiol Lung Cell Mol Physiol, 282:L944-56.
25. Horvath I et al. 2005. Exhaled breath condensate: methodological recommendations and unresolved questions. Eur Respir J, 26:523-48.
26. Janssen LJ, 2001. Isoprostanes: an overview and putative roles in pulmonary pathophysiology. Am J Physiol Lung Cell Mol Physiol, 280: L1067-82.
27. Kang KH et al. 1993. Airway and vascular effects of 8-epi-prostaglandin F2 alpha in isolated perfused rat lung. J Appl Physiol, 74:460-5.
28. Kasielski M, Nowak D. 2001. Long-term administration of N-acetylcysteine decreases hydrogen peroxide exhalation in subjects with chronic obstructive pulmonary disease. Respir Med, 95:448-56.
29. Kawikova I et al. 1996. 8-Epi-PGF2 alpha, a novel noncyclooxygenase-derived prostaglandin, constricts airways in vitro. Am J Respir Crit Care Med, 153:590-6.
30. Kharitonov SA et al. 1995. Acute and chronic effects of cigarette smoking on exhaled nitric oxide. Am J Respir Crit Care Med, 152:609-12.
31. Ko FW et al. 2006. Exhaled breath condensate levels of 8-isoprostane, growth related oncogene alpha and monocyte chemoattractant protein-1 in patients with chronic obstructive pulmonary disease. Respir Med, 100:630-8.
32. Kostikas K et al. 2002. pH in expired breath condensate of patients with inflammatory airway diseases. Am J Respir Crit Care Med, 165:1364-70.
33. Kostikas K et al. 2003. Oxidative stress in expired breath condensate of patients with COPD. Chest, 124:1373-80.
34. Maziak W et al. 1998. Exhaled nitric oxide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 157:998-1002.
35. Moncada S, Palmer RM, Higgs EA. 1991. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev, 43:109-42.
36. Montuschi P. 2005, Exhaled breath condensate analysis in patients with COPD. Clin Chim Acta, 356:22-34.
37. Montuschi P et al. 2000. Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. Am J Respir Crit Care Med, 162:1175-7.
38. Montuschi P, Kharitonov SA, Barnes PJ. 2001. Exhaled carbon monoxide and nitric oxide in COPD. Chest, 120:496-501.
39. Morrow JD, Roberts LJ. 1997. The isoprostanes: unique bioactive products of lipid peroxidation. Prog Lipid Res, 36:1-21.
40. Morrow JD, Roberts LJ. 2002. The isoprostanes: their role as an index of oxidant stress status in human pulmonary disease. Am J Respir Crit Care Med, 166: S25-30.
41. [NAEPP] National Asthma Education and Prevention Program. 2006. Expert panel report: Guidelines for diagnosis and managment of asthma.
42. Update on Selected Topics 2002. 02-5074. 2003. Bethesda, MD: National Institutes of Health.
43. [NHLBI] National Heart, Lung and Blood Institute and World Health Organization. 2005. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. Updated 2003. Bethesda, MD: National Heart, Lung and Blood Institute.
44. 2 and thiobarbituric acid reactive substances (TBARs) by healthy subjects. Free Radic Biol Med, 30:178-86.
45. Nowak D et al. 1999. Increased content of thiobarbituric acid-reactive substances and hydrogen peroxide in the expired breath condensate of patients with stable chronic obstructive pulmonary disease: no significant effect of cigarette smoking. Respir Med, 93:389-96.
46. O'Reilly PJ et al. 2006. Detection of proinflammatory peptides in exhaled breath condensate of COPD patients and healthy controls [abstract]. Proc Am Thorac Soc, 3:AI 27.
47. Papi A et al. 2000. Partial reversibility of airflow limitation and increased exhaled NO and sputum eosinophilia in chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 162:1773-7.
48. Rahman I et al. 2002. 4-Hydroxy-2-nonenal, a specific lipid peroxidation product, is elevated in lungs of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 166:490-5.
49. Repine JE, Bast A, Lankhorst I. 1997. Oxidative stress in chronic obstructive pulmonary disease. Oxidative Stress Study Group. Am J Respir Crit Care Med, 156:341-57.
50. Roberts LJ, Morrow JD. 2000. Measurement ofF(2)-isoprostanes as an index of oxidative stress in vivo. Free Radic Biol Med, 28:505-13.
51. Rutgers SR et al. 1999. Markers of nitric oxide metabolism in sputum and exhaled air are not increased in chronic obstructive pulmonary disease. Thorax, 54:576-80.
52. Shapiro SD et al. 2003. Neutrophil elastase contributes to cigarette smoke-induced emphysema in mice. Am J Pathol, 163:2329-35.
53. Shapiro SD, Ingenito EP. 2005. The pathogenesis of chronic obstructive pulmonary disease: advances in the past 100 years. Am J Respir Cell Mol Biol, 32:367-72.
54. Smith AD et al. 2005. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med, 352:2163-73.
55. Stone PJ et al. 1995. Elastin and collagen degradation products in urine of smokers with and without chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 151:952-9.
56. van Beurden WJ et al. 2003. Effects of inhaled corticosteroids with different lung deposition on exhaled hydrogen peroxide in stable COPD patients. Respiration, 70:242-8.
57. Weathington NM et al. 2006. A novel peptide CXCR ligand derived from extracellular matrix degradation during airway inflammation. Nat Med.